Wiseheart Medval Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $13.7M

  • Investors
  • 5

Wiseheart Medval General Information

Description

Developer of drugs designed for cell therapy for neurological diseases. The company uses somatic cell reprogramming technology and non-integrated system to directly induce neural stem cells (iNSCs) from human peripheral blood mononuclear cells or fibroblasts, and can efficiently differentiate into specific nerve cells thereby, providing patients who have Parkinson's disease and other neurological diseases with effective drugs.

Contact Information

Website
www.wiseheartmed.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • K301, Innovation Building, Number 29, Life Science Park Road
  • Changping District, Beijing
  • Beijing, 102206
  • China
+86 130
Primary Industry
Biotechnology
Corporate Office
  • K301, Innovation Building, Number 29, Life Science Park Road
  • Changping District, Beijing
  • Beijing, 102206
  • China
+86 130

Wiseheart Medval Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Wiseheart Medval Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 06-Jan-2025 $13.7M Completed Generating Revenue
3. Early Stage VC 22-Feb-2024 Completed Generating Revenue
2. Seed Round 09-Jun-2022 Completed Generating Revenue
1. Seed Round 25-Oct-2021 Completed Startup
To view Wiseheart Medval’s complete valuation and funding history, request access »

Wiseheart Medval Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

Wiseheart Medval Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026228279-A1 Ex vivo cortical interneuron progenitor cell population, preparation method therefor, and use thereof Pending 28-Apr-2025

Wiseheart Medval Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing Energy Tongxin Investment Venture Capital Minority
Wuhan Innovation Investment Government Minority
Beijing Innovation Industry Investment Venture Capital Minority
Hangzhou Jiuzhi Investment Management Growth/Expansion Minority
Green Pine Capital Partners Venture Capital Minority
To view Wiseheart Medval’s complete investors history, request access »

Ready to get started?

Request a free trial

Wiseheart Medval FAQs

  • When was Wiseheart Medval founded?

    Wiseheart Medval was founded in 2021.

  • Where is Wiseheart Medval headquartered?

    Wiseheart Medval is headquartered in Beijing, China.

  • What industry is Wiseheart Medval in?

    Wiseheart Medval’s primary industry is Biotechnology.

  • Is Wiseheart Medval a private or public company?

    Wiseheart Medval is a Private company.

  • What is Wiseheart Medval’s current revenue?

    The current revenue for Wiseheart Medval is .

  • How much funding has Wiseheart Medval raised over time?

    Wiseheart Medval has raised $13.7M.

  • Who are Wiseheart Medval’s investors?

    Beijing Energy Tongxin Investment, Wuhan Innovation Investment, Beijing Innovation Industry Investment, Hangzhou Jiuzhi Investment Management, and Green Pine Capital Partners have invested in Wiseheart Medval.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process